TD Cowen raises Centene stock price target on strong earnings beat

Centene reported first-quarter 2026 adjusted EPS of $3.37, beating consensus of $2.23, and raised full-year 2026 EPS guidance to greater than $3.40 from prior guidance, implying a 13% increase. Management said results exceeded internal expectations by $0.50 per share, while revenue of $49.94B also topped estimates. TD Cowen lifted its price target to $47 from $38 and maintained Hold; Cantor Fitzgerald upgraded to Overweight and Mizuho raised its target to $50 from $41.

Analysis

CNC’s print is less about a one-off earnings beat and more about a reset in the market’s view of Medicaid managed care margin durability. The second-order read-through is that utilization is not normalizing as fast as feared, which should ease pressure on the entire government-sponsored MCO cohort and reduce the need for aggressive reserve-building into year-end. That said, the reaction also raises the bar: once a stock re-rates on a guidance reset, the next leg depends on whether peers can validate the same pricing/MLR discipline rather than just one company outperforming.

The clearest beneficiaries are the other large-cap managed care names with similar government exposure, especially where investor positioning was still anchored to margin compression. If CNC’s improved outlook proves repeatable, the market may start discounting a broader 2027 earnings power reset across the group, which would favor names with operating leverage to stable medical cost trends. The loser is not another insurer per se, but any healthcare services or provider names that were implicitly relying on continued payer pressure; better payer margins can translate into tougher reimbursement negotiations and slower rate concessions.

The contrarian risk is that this is being priced as a clean fundamental turn when it may just be a favorable flu/utilization quarter plus conservative reserve assumptions. If health exchange risk adjustment comes in weaker than management implies, or if Medicare pressure re-accelerates, the stock could give back a meaningful portion of the recent move over the next 1-2 reporting cycles. At this level, the market is effectively paying ahead for sustained upside revisions, so any disappointment on utilization or state rate updates is likely to hit multiple before earnings.

Key Decisions for Investors

• Maintain a tactical long in CNC for 4-8 weeks, but only as a momentum trade; treat the recent rerating as extended and use a 10-12% trailing stop because any reserve or utilization miss could unwind the move quickly.
• Go long ELV / short CNC as a relative-value hedge if you want to express the thesis that the market has already fully priced CNC’s reset; the pair should work if CNC’s rerating stalls while peers remain under-owned.
• Add a basket long in managed care names with cleaner Medicare/Medicaid mix over the next 1-2 months, but only on pullbacks; the trade is for multiple expansion, not another earnings surprise.
• Buy downside protection on CNC into the next guidance-sensitive event using 1-2 month puts or put spreads; skew is likely still cheap relative to the risk of a reversal if exchange assumptions disappoint.